Clinical Trial Update: A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for SHR6390 in combination with letrozole, anastrozole, or fulvestrant in HR-positive, HER2-negative advanced breast cancer (Phase 1/2; co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Anastrozole (Anastrozole)
• Fulvestrant (fulvestrant)
• Letrozole (letrozole)
• SHR6390 (SHR6390)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Advanced Breast Cancer | Phase 1, Phase 2 | Status: COMPLETED